晚期非小细胞肺癌EGFR基因状态与抗血管生成治疗疗效相关性的研究进展  

Research progress on the correlation between EGFR gene status and the efficacy of anti-angiogenic therapy in advanced non-small cell lung cancer

作　　者：史孟楠 黄芳[1] 姜达[1] SHI Mengnan;HUANG Fang;JIANG Da(Department of Oncology,the Fourth Hospital of Hebei Medical University,Hebei Shijiazhuang 050011,China.)

机构地区：[1]河北医科大学第四医院肿瘤内科,河北石家庄050011

出　　处：《现代肿瘤医学》2024年第19期3801-3808,共8页Journal of Modern Oncology

基　　金：河北省卫生健康委政府资助临床医学优秀人才培养项目(编号:冀财社〔2019〕139号)。

摘　　要：肺癌是全球死亡率最高的恶性肿瘤。为提高整体治疗效果,目前抗血管生成治疗已成为晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)治疗的重要组成部分,且已有研究发现该类药物的疗效与表皮生长因子受体(epidermal growth factor receptor,EGFR)基因状态有着一定关系,并提示血管内皮生长因子受体(vascular endothelial growth factor receptor,VEGFR)和EGFR双重阻断可能是NSCLC治疗的新选择。该文基于国内外多项抗血管生成药物治疗晚期NSCLC的发展现状,综述了EGFR基因状态与不同抗血管生成药物疗效的相关性,及抗血管生成药物联合EGFR酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKI)对特殊部位转移的EGFR突变患者的疗效,同时对未来联合抗血管生成药物治疗NSCLC的可能新模式进行展望。Lung cancer is the most deadly malignant tumor in the world.In order to improve the overall therapeutic effect,anti-angiogenesis therapy has become an important part of the treatment of advanced non-small cell lung cancer(NSCLC).In addition,some studies have found that there is a certain relationship between the efficacy of these drugs and the gene status of epidermal growth factor receptor(EGFR)gene.These findings suggest that the dual blockade of vascular endothelial growth factor receptor(VEGFR)and EGFR may be a new option for NSCLC.Based on the development status of a number of anti-angiogenic drugs in the treatment of advanced NSCLC at home and abroad,this paper reviewed the correlation between EGFR gene status and efficacy of different anti-angiogenic drugs,and efficacy of anti-angiogenic drugs combined with EGFR tyrosine kinase inhibitors(TKI)in patients with EGFR mutations and special site metastasis,at the same time,the possible new mode of combined anti-angiogenic drugs in the treatment of NSCLC was prospected.

关 键 词：抗血管治疗 肺肿瘤 表皮生长因子受体 血管内皮生长因子受体 

分 类 号：R734.2[医药卫生—肿瘤]